Business
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.
About this update from Akeso, Inc.
[{"type":"text","content":"Key Highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD).","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS HR=0.51; sNDA under priority review.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Cadonilimab approved for first-line gastric cancer: Fills immunotherapy gap for patients with low or negative PD-L1 expression.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Cadonilimab's sNDA for first-line cervical cancer accepted by NMPA.","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"New commercial milestones: cadonilimab and ivonescimab added to the National Reimbursement Drug List (NRDL).","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"AK117 (CD47) enters Phase III trials: ivonescimab combined with AK117 for first-line HNSCC treatment, compared with pembrolizumab.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Cadonilimab and ivonescimab: Over 20 Phase III and 40+ Phase II trials ongoing, covering 40+ indications.","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":""IO+ADC" 2.0 strategy gaining momentum: First self-developed ADC and bispecific ADC enter clinical trials.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-oncology expansion: ebronucimab (PCSK9) approved, NDAs for ebdarokimab (IL-12/IL-23) and gumokimab (IL-17) under review.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"3 drugs approved, 5 new drugs with 5 indications under regulatory review.","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1185,"olType":false},{"type":"text","content":"HONG KONG, March 30, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.","length":250,"tagName":"p"},{"type":"text","content":"In 2024, Akeso achieved key success in antibody therapy resea...